
Bioverativ was spun off from Biogen in 2017, and its stock symbol is BIVV. This move marked a significant shift in the company's focus on rare blood disorders, particularly hemophilia.
As a separate entity, Bioverativ has been able to tailor its approach to these conditions, which is reflected in its product portfolio. The company's main product is ELOCTA, a treatment for hemophilia A.
ELOCTA has been a game-changer for patients with hemophilia A, offering a more convenient and effective treatment option. Its success has helped establish Bioverativ as a leader in the hemophilia space.
If this caught your attention, see: Stock Symbol B
Performance Reports
Bioverativ's performance reports show a significant increase in revenue.
In 2017, the company's full year revenue rose by 31.7% compared to the previous year.
The fourth quarter of 2017 also saw a revenue boost, with a 28.3% year-over-year increase.
Bioverativ's operating margin for the full year 2017 was a notable achievement.
Hemophilia Spinoff
Bioverativ is a new company spun out from Biogen's global hemophilia business, which will begin trading common shares on the NASDAQ Global Select Market.
If this caught your attention, see: Global Payments Stock Symbol
The spinoff is expected to be completed on February 1, and Biogen shareholders will receive one share of Bioverativ's stock for every two shares of Biogen held as of January 17.
Bioverativ will focus on R&D and commercialization of new therapies for hemophilia and other rare blood disorders.
The company aims to become the leading hematology rare disease company committed to creating significant progress for patients.
Bioverativ's pipeline includes several preclinical prospects, including BIVV 001, a once-weekly or less frequent treatment for hemophilia A.
BIVV 001 is an engineered Factor VIII molecule with a region of Fc dimer, D’D3 domains of von Willebrand factor, and polypeptides developed through the XTEN half-life extension technology.
Some of the other pipeline candidates include BIVV 002, a subcutaneous hemophilia B candidate, and candidates for beta thalassemia and sickle cell disease.
Here are some of the pipeline candidates in more detail:
- BIVV 002: A subcutaneous hemophilia B candidate that combines Fc dimer and XTEN technology along with R338L Padua Factor IX variant.
- Beta thalassemia and sickle cell disease candidates: To be generated through a collaboration with Sangamo BioSciences using their genome-editing technology platform.
- Lentiviral gene transfer vector-based gene therapies for hemophilia A and hemophilia B: To be developed through a collaboration with a joint venture of Italy’s Fondazione Telethon and Ospedale San Raffaele.
- A Factor VIIIa mimetic bispecific antibody indicated for hemophilia A and inhibitors: Whose method of action is undisclosed.
- Multiple early-stage programs for sickle cell: Whose methods of action are also undisclosed.
Frequently Asked Questions
When did Sanofi buy Bioverativ?
Sanofi acquired Bioverativ on March 8, 2018, for $105 per share in cash. This marked a significant milestone in Sanofi's expansion into the rare blood disorder market.
Sources
- https://www.marketscreener.com/quote/stock/BIOVERATIV-INC-33339375/
- https://www.forbes.com/sites/joecornell/2018/01/31/biogen-spin-off-bioverativ-to-be-acquired/
- https://www.advfn.com/stock-market/NASDAQ/BIVV/stock-price
- https://www.genengnews.com/news/biogen-hemophilia-spinoff-bioverativ-begins-trading-shares/
- https://www.stockspinoffs.com/tag/gabelli/
Featured Images: pexels.com